Inflammation at the Helm | Ep. 1037
Reprogramming the Brain’s Immune Axis to Rewrite Neurodegeneration
Hello Avatar! Welcome back for another week of biotech analysis. Today is Sunday, which means this is our Building Biotech newsletter that is focused on discussing biopharma strategy topics. This week, we’re diving into one of the most overlooked yet pivotal forces in neurology - neuroinflammation. A recent review in Science Translational Medicine reframes the field with surprising clarity: inflammation isn’t just a symptom of neurodegeneration, it’s a programmable driver. From BTK inhibitors in progressive MS to C1q antibodies in post-stroke dementia, the brain’s immune circuits are emerging as high-leverage therapeutic nodes. We unpack the targets, timelines, and translational strategies that could redefine how we approach AD, PD, stroke, and beyond.
We are now publishing 7x per week according to the following cadence:
Mondays: Stocks
Tuesdays: Biotech
Wednesdays: Podcast
Thursdays: Markets
Fridays: News
Saturdays: Podcast
Sundays: Strategy
We are also publishing unique content on X - be sure to follow up if you are not already @BowTiedBiotech. And to check-out the archive of our work on X you can find it on our website at: BowtiedBiotech.subtack.com/x-articles.
SUBSCRIBE TO PODCAST HERE:
Please help spread the work by subscribing and hitting the share button if you are enjoying our bi-weekly newsletters!
Enough shilling for the day, lots to cover this week, let's get started!
Introduction: The Microglial Hour Is Upon Us
Neuroinflammation isn’t just a passenger in neurodegenerative disease, it’s the co-pilot. Decades of work framed inflammation as a response to injury, a cleanup crew summoned too late to matter. But new data flips that view.
From MS to stroke to Alzheimer’s and Parkinson’s, inflammation doesn’t just follow damage, it shapes it, sustains it, and in some cases, initiates it.
A recent review in Science Translational Medicine crystallizes the field’s inflection point. The brain's immune architecture isn’t a monolith, it’s a layered, dynamic system where microglia, astrocytes, infiltrating leukocytes, and complement proteins orchestrate a slow spiral of damage. And yet, with precision tools in hand (e.g., BTK inhibitors, C1q antibodies, TREM2 agonists) we finally have a chance to steer the course.
For biotech investors and translational scientists, this is a new design space. Think beyond traditional labels like MS or AD. These aren’t diseases, they’re overlapping circuits of immune dysfunction. Fix the circuit, and you may fix them all.
